Steven Rabinowe, MD
Endocrinology, Diabetes & Metabolism · Racine, WINPI 1386759389
Payments from drug & device makers
Across 1,113 payments — averaging $309.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$138K
- Boehringer Ingelheim$52K
- Novo Nordisk$52K
- Johnson & Johnson$27K
- Merck$26K
- AstraZeneca$24K
- plus $26K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 249 | $137,734 |
| Boehringer Ingelheim | 158 | $51,828 |
| Novo Nordisk | 266 | $51,747 |
| Johnson & Johnson | 36 | $26,755 |
| Merck | 67 | $25,863 |
| AstraZeneca | 98 | $23,602 |
| Bayer | 24 | $13,501 |
| Sanofi-aventis U.S. LLC | 39 | $5,705 |
| Amgen(2 entities) | 21 | $4,777 |
| Dexcom, Inc. | 69 | $999 |
| AbbVie | 26 | $420 |
| IBSA Pharma Inc. | 16 | $270 |
| Amneal Pharmaceuticals LLC | 9 | $146 |
| Medtronic | 2 | $134 |
| Amarin Pharma, Inc. | 6 | $110 |
| Corcept Therapeutics | 6 | $95 |
| Abbott | 5 | $77 |
| Tandem Diabetes Care, Inc. | 3 | $56 |
| Shire North American Group Inc | 3 | $51 |
| Novartis | 2 | $38 |
| Mannkind Corporation | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Antares Pharma, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $3 |
How this compares
$344,020 in reported general payments places this provider in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Racine
- Neil BinkleyMadison$556K
- Anoop Mohamed IqbalGreenfield$405K
- Adriana IoachimescuMilwaukee$370K
- Aron AdkinsEau Claire$349K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$85K
- Vinay PatelNeenah$64K
- Bradley JavorskyMenomonee Falls$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.